CERVIVA was established in 2005 and was initially funded by the HRB Health Services Research Award scheme to perform high quality research in the area of cervical screening in Ireland, with an overarching aim of supporting CervicalCheck [the National Cervical Screening Programme]. Through phase 1 funding, CERVIVA has been a very successful health services based research consortium, which has effectively bridged the gap between academic research and health services and clinical research.

Knowledge of, attitudes towards and psychosocial impact of cervical screening, HPV infection, testing and vaccination


  • Phase I: CERVIVA
Group of girls

Cervical cancer is the second most common female malignancy worldwide. There are approximately 200 new cases diagnosed and 70 deaths annually in Ireland. A number of factors are known to be associated with increased risk of cervical cancer including smoking and infection with human papilloma virus (HPV).

Subscribe to RSS - Phase I: CERVIVA